Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
401 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 26
402 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 40
403 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 68
404 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
405 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms Hematology 2026 Standard Therapy Spain 65
406 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 63
407 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 58
408 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 44
409 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 61
410 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 54
411 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Poland 11
412 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 64
413 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 64
414 Apheresis autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 32
415 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
416 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 54
417 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
418 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 72
419 Apheresis autologous Peripheral T-cell Lymphoma Hematology 2026 Standard Therapy Germany 56
420 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
421 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
422 Apheresis autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 47
423 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
424 Apheresis allogeneic Vexas-Syndrome with UBA1-Mutation Hematology 2026 Standard Therapy Germany 67
425 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 27
426 Apheresis allogeneic Primary Myelofibrosis PMF Hematology 2026 Standard Therapy Poland 57
427 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 48
428 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 67
429 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 42
430 Apheresis allogeneic MPS-I: Hurler Syndrome Hematology 2026 Standard Therapy Russia 1
431 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 29
432 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 47
433 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 66
434 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 4
435 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
436 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 63
437 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Lithuania 40
438 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 68
439 Apheresis allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Netherlands 61
440 Apheresis allogeneic Acute Lymphoblastic leukemia Hematology 2026 Standard Therapy Germany 21
441 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 72
442 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 36
443 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
444 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 63
445 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 54
446 Apheresis allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 54
447 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 76
448 Apheresis allogeneic Myelodysplastic Disorders Hematology 2026 Standard Therapy France 73
449 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 75
450 Apheresis allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 47
451 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 68
452 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 40
453 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Macedonia 59
454 Apheresis allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy Belgium 4
455 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Australia 13
456 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
457 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 38
458 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Russian Federation 28
459 Apheresis allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 58
460 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 54
461 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
462 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy United Kingdom 20
463 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
464 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 69
465 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 64
466 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 56
467 Apheresis autologous Myeloma Hematology 2026 Standard Therapy Portugal 42
468 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
469 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
470 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 71
471 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
472 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 24
473 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 67
474 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 62
475 Apheresis Autologous Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 43
476 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 60
477 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
478 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
479 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
480 Apheresis Allogeneic Primary Myelopathic Polycythemia Hematology 2026 Standard Therapy Germany 67
481 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
482 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
483 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
484 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 32
485 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
486 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
487 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 42
488 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 65
489 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Germany 73
490 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
491 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Italy 6
492 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
493 Apheresis Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy India 3
494 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 32
495 Apheresis Allogeneic Mixed-Phenotype Acute Leukemia Hematology 2026 Standard Therapy Poland 40
496 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 64
497 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 58
498 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
499 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 45
500 Apheresis Allogeneic T-cell non-Hodgkin Lymphoma (Mycosis Fungoides) Hematology 2026 Standard Therapy Portugal 43
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?